At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 101 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4 Study of Nivolumab in Combination With Ipilimumab in Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate-or Poor-risk Factors Conducted in India
In Brief
A Phase 4 clinical trial evaluating Nivolumab and Ipilimumab for Kidney Neoplasms. Completed, enrolled 101 participants across 11 sites.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of nivolumab combined with ipilimumab in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC) or metastatic RCC (mRCC) in India.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Neoplasms
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartDec 2020
Primary CompletionJan 2024
TodayJul 2026
First PostedAug 14, 2020
Enrollment StartDec 17, 2020
Primary CompletionJan 4, 2024
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.9 years ago
Interventions
Nivolumabbiological
Specified dose on specified days
Ipilimumabbiological
Specified dose on specified days